Skip to main content
Home
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
      • Specialties
        • Vaccines & Infectious Diseases
        • Ophthalmology
        • Clinical Neuroscience
        • Rare Disease
        • Cell & Gene Therapy
        • Government
      • Additional Specialties
        • Hematology
        • Oncology
        • Maternal & Child Health
        • Medical Devices
      • Clinical Services
        • Biostatistics
        • Clinical Data Management
        • Clinical Research Services
        • Clinical Trial Management
        • Global Regulatory Affairs
        • Pharmacovigilance & Medical Monitoring
    • Veridix - Tech & AI
      • eClinical Platform
        • EDC
        • Decentralized Clinical Trials
        • Health Navigator
        • RTSM
        • eCOA / ePRO
      • AI Agents
        • Biostats and Analysis Agent
        • Data Management Agent
        • Document Authoring
      • GlobalTrace
      • Analytics & Reporting
        • Clinical Pipelines
        • VERA
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Breadcrumb

  1. Emmes Group

Paclitaxel Activity in Heavily Pretreated Breast Cancer: A National Cancer Institute Treatment Referral Center Trial

Go back to Resources

Paclitaxel Activity in Heavily Pretreated Breast Cancer: A National Cancer Institute Treatment Referral Center Trial

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Abstract:

Go back to Resources

Paclitaxel activity in heavily pre-treated breast cancer: A National Cancer Institute Treatment Referral Center trial,

Go back to Resources

Paclitaxel activity in heavily pre-treated breast cancer: A National Cancer Institute Treatment Referral Center trial,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Normal behaviour of circulatory parameters during exercise. Reference values for heart rate and systemic blood pressure. The ECCIS Project data. Epidemiologia e Clinica della Cardiopatia Ischemica Silente],

Go back to Resources

Normal behaviour of circulatory parameters during exercise. Reference values for heart rate and systemic blood pressure. The ECCIS Project data. Epidemiologia e Clinica della Cardiopatia Ischemica Silente],

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer,

Go back to Resources

Meeting highlights: a reappraisal of research results for the local treatment of early stage breast cancer,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Meeting Highlights: A Reappraisal of Research Results For the Local Treatment of Early Stage Breast Cancer

Go back to Resources

Meeting Highlights: A Reappraisal of Research Results For the Local Treatment of Early Stage Breast Cancer

Authors:

Secondary:

Volume:

Pagination:

URL:

Keywords:

Go back to Resources

Impact of HLA matching, type of crossmatch and immunosuppresive therapy on primary pediatric cadaver renal allograft survival,

Go back to Resources

Impact of HLA matching, type of crossmatch and immunosuppresive therapy on primary pediatric cadaver renal allograft survival,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Growth post transplantation (Tx) - Long term analysis by the North American Pediatric Renal Transplant Cooperative Study,

Go back to Resources

Growth post transplantation (Tx) - Long term analysis by the North American Pediatric Renal Transplant Cooperative Study,

Authors:

Location:

Go back to Resources

Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates,

Go back to Resources

Fourth annual survey of worldwide HIV, SIV, and SHIV challenge studies in vaccinated nonhuman primates,

Authors:

Secondary:

Volume:

Pagination:

Go back to Resources

Evaluation of HIV-1 MN recombinant gp160 candidate vaccine,

Go back to Resources

Evaluation of HIV-1 MN recombinant gp160 candidate vaccine,

Authors:

Location:

Go back to Resources

Strategies for safety reporting in substance abuse trials.

Go back to Resources

Strategies for safety reporting in substance abuse trials.

Authors:

Secondary:

Volume:

Pagination:

Issue:

PMID:

DOI:

Keywords:

Abstract:

Go back to Resources

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 95
  • Page 96
  • Page 97
  • Page 98
  • Current page 99
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to
Emmes Group

Delivering Global Health
Impact Through People,
Science and Technology

Main navigation
  • Company
    • History
    • Leadership
    • Clients and Collaborators
    • By the Numbers
  • Capabilities
    • Emmes - CRO
    • Veridix - Tech & AI
  • Resources
    • Newsroom
    • Blog
  • Careers
  • Contact
    • Locations
    • Contact Us

Copyright ©, The Emmes Company, LLC

Footer
  • Cookie Policy
  • External Privacy Notice
  • FCOI
  • Emmes EU-U.S. Data Privacy Framework
  • Purchasing Terms and Conditions